Safety evaluation of Datopotamab deruxtecan for triple-negative breast cancer: a meta-analysis
Background: TROP-2 is emerging as a valid and fruitful strategy in triple-negative breast cancer (TNBC) patients, and several agents are currently under evaluation, including Datopotamab deruxtecan (Dato-DXd). Research design and methods: Herein, we performed a meta-analysis aimed to evaluate any gr...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Elsevier
2023-01-01
|
| Seri Bilgileri: | Cancer Treatment and Research Communications |
| Konular: | |
| Online Erişim: | http://www.sciencedirect.com/science/article/pii/S2468294223000977 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|